On behalf of Daiichi Sankyo, Inc. and AstraZeneca, we cordially invite you to join us for an informative, expert-led presentation on:
See How ENHERTU Is Redefining HER2-Expressing mBC Care For Eligible Patients
This program will cover:
► A HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of
1)patients with hormone receptor (HR)-positive HER2-low (IHC 1 + or IHC 2+/ISH-) or HER2-ultralow (IHC O with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting, and
2) HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen
► The unmet need for patients with HER2-low (IHC 1+ or IHC 2+/ISH-) and HER2-ultralow (IHC O with membrane staining) expressing mBC
► The efficacy of ENHERTU for patients with HR+, HER2-low (IHC 1+ or IHC 2+/ISH-) and HER2-ultralow (IHC O with membrane staining) mBC
► The unmet need in HER2-positive (IHC 3+ or ISH positive) mBC and the efficacy data of ENHERTU in patients with HER2-positive (IHC 3+ or ISH positive) mBC
► The safety profile and management strategies for ENHERTU
Date: Apr 15th, 2025
Time: 6:00 PM - 8:00 PM Central Standard Time
Location: The Waterfront Restaurant and Tavern
328 Front Street South
La Crosse, WI 54601
Faculty: Amy Krie, MD
Allina Health Cancer Institute Piper Breast Center Minneapolis
RSVP
Ashley Link
(612) 7703105 or ashley.link@astrazeneca.com
By: 4/12/2025